Astrazeneca ADR Stock
€70.50
Your prediction
Financial data and news for AstraZeneca
sharewise wants to provide you with the best news and tools for AstraZeneca, so we directly link to the best financial data sources.
Financials
News
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
AstraZeneca Plc (NASDAQ: AZN)Q4 2023 Earnings CallFeb 08, 2024, 6:45 a.m. ET
Andy Barnett
Source Fool.com
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge
Is Now the Right Time to Buy AstraZeneca Stock?
With shares of AstraZeneca (NASDAQ: AZN) returning 55% over the last three years, easily topping the market's return of 29%, it's no surprise why investors might be curious about whether there's
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Weight-loss drugs present an enormous opportunity in the healthcare market. Wegovy and Mounjaro are some of the top-selling drugs available in that indication, and companies that make them -- Novo
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
U.K.-based AstraZeneca (NASDAQ: AZN) is now gearing up for the second time to develop a challenger to Novo Nordisk's (NYSE: NVO) Ozempic, its absurdly successful treatment for type 2 diabetes. If
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
AstraZeneca Plc (NASDAQ: AZN)Q3 2023 Earnings CallNov 09, 2023, 9:00 a.m. ET
Operator
Source Fool.com
3 No-Brainer Stocks to Buy for Under $100 Right Now
Benjamin Franklin would probably be disappointed that the $100 bill that bears his likeness isn't worth what it used to be. However, there are actually plenty of great stocks to be found that you
AstraZeneca: Rebound in 2024 with double-digit earnings growth
U.K.-based AstraZeneca PLC (NASDAQ: AZN) is up 8.95% in the past month as investors grow optimistic about the company's improved earnings outlook for 2024. Not only are sales of cancer and
3 stocks that crushed earnings estimates and still tanked
Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case. Every earnings season, regardless of sector or industry, has its share of stocks that report